Non-Small Cell Lung Cancer Coverage from Every Angle
Editor:
David S. Ettinger, MD
Advertisement
Advertisement

Videos

Bernardo H.L. Goulart, MD: How Do You Tell Patients That Money Matters in NSCLC Treatment?

Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Treatment Update on BLU-667

Suresh S. Ramalingam, MD, on Managing Pyrexia With Dabrafenib/Trametinib in Advanced NSCLC

David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Shirish M. Gadgeel, MD, on Advanced Non–Small Cell Lung Cancer: Integrating Chemotherapy and Immunotherapy

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: Is There Still a Role for Chemotherapy?

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Predicting Survival Outcomes

Leora Horn, MD, on Managing the Adverse Events of Combination Therapies

Jessica S. Donington, MD, on Treating Early-Stage Thoracic Cancers

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Clinical Implications of Using a New Algorithm to Predict Response to Immunotherapy

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: Reducing the Frequency of Nivolumab Dosing

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy Perspectives

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Leora Horn, MD, on NSCLC: The Path Forward for ALK Inhibitors and Immunotherapy

Mark G. Kris, MD, on NSCLC: Juggling Sequence and Agent Choices in Lung Cancer

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Karen Reckamp, MD, on Metastatic NSCLC: Targeted Treatment Updates

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient’s Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

Roy S. Herbst, MD, PhD, on Lung Cancer: Update on Immunotherapy

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Martin Reck, MD, PhD, on Selecting Immunotherapy

Kathrin Milbury, PhD, on Patients With Lung Cancer: Benefits of Yoga

Luis G. Paz-Ares, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Silvia Formenti, MD, on Combining Immunotherapy and Radiation Therapy

Clemens Grassberger, PhD, on NSCLC: Therapy Sequencing Criteria

Mariano Provencio, MD, PhD, on NSCLC: Results From the NADIM and NORA Trials

Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

Virginie Westeel, MD, PhD, on NSCLC: Results From the IFCT-0302 Trial

Tony Mok, MD, on Oncogene-Addicted NSCLC: Expert Perspective on the Challenges

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD: Results From the ARCHER 1050 Trial

Ramaswamy Govindan, MD, and Yi-Long Wu, MD: Results From the CTONG ADJUVANT Trial

Ramaswamy Govindan, MD, and Jaafar Bennouna, MD: Results From the AvaALL Trial

David S. Ettinger, MD, and Matthew A. Gubens, MD: Immunotherapies for Lung Cancer

Gregory J. Riely, MD, PhD, and David S. Ettinger, MD: The What, When, and How of Biomarker Testing

Wallace Akerley, MD, and David S. Ettinger, MD: Biomarker-Based Treatment Selection

Stephanie Andrews, MS, ANP-BC, on Managing Toxicities of Immunotherapies

David S. Ettinger, MD, on The Importance of the NCCN Guidelines in Lung Cancer

Daniel R. Gomez, MD, on Immunotherapy in Lung Cancer and the Value Proposition

Walter J. Curran, MD, on Stage III NSCLC

Benjamin Movsas, MD, and Quynh Nguyen, MD, on Quality of Life and Palliative Care in Lung Cancer

Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

Virginie Westeel, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

The JNCCN Spotlight

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.